Carvana’s Brick-and-Mortar Turn: A Trader’s Diary

Units of Stellantis stock acquired (against my better judgement): 50. Hours spent questioning my life choices: escalating. Number of times I’ve considered becoming a shepherd: 3.

Units of Stellantis stock acquired (against my better judgement): 50. Hours spent questioning my life choices: escalating. Number of times I’ve considered becoming a shepherd: 3.

Oracle, that oracle of database and, increasingly, of caution, has become the harbinger of potential overreach. Its warnings echo through the canyons of Wall Street, a reminder that even the most robust of booms are built on foundations of sand. Yet, Nvidia persists, seemingly immune to the gathering storm. This resilience is not merely a matter of technological prowess; it is a testament to the intoxicating power of belief – a collective delusion, perhaps, that sustains itself on its own momentum.

The comparison, at first glance, appears straightforward. Both aim to replicate the performance of the aforementioned index, a collection of smaller enterprises deemed worthy of inclusion by an unseen committee. However, the details, as always, are where the disquiet resides. The funds differ in size, expense ratio, and yield – distinctions so minute they threaten to dissolve entirely upon closer inspection, leaving one questioning the very purpose of measurement.

This whole Strait of Hormuz situation is, shall we say, inconvenient. It’s like someone put a cork in the world’s oil bottle. And naturally, everyone’s blaming everyone. The President promised it’d be over in weeks? Bless his heart. He’s an optimist. I’m a realist… with a healthy dose of skepticism. The Middle East? It’s a region where “weeks” can stretch into decades. But enough geopolitical hand-wringing. Let’s talk money. Specifically, South Korean money.

NextEra, a hybrid of regulated utility and burgeoning renewable enterprise, presents itself as a kind of temporal paradox. Its strength lies not simply in generating power, but in anticipating the needs of a future already taking shape – a future driven by the insatiable appetite of artificial intelligence and the relentless pressure of population density. The company, anchored by Florida Power & Light, operates as a conduit, channeling energy through a landscape simultaneously familiar and transformed. Its recent performance – a 27% increase in stock value over the past year – is not an anomaly, but a consequence of its position at the intersection of necessity and innovation. The market, as ever, assigns a premium to such advantageous positioning, a premium currently reflected in a forward P/E ratio exceeding the sector average.

But a man can look at a parched field and see the ghost of green beneath the surface. I believe much of the trouble that’s been weighing on UnitedHealth is already priced into the stock, a burden carried and accounted for. Investors, it seems, are forgetting just how deeply rooted this company is, how much of the healthcare landscape it commands. It remains a giant, straddling both the world of insurance and the business of care itself.
The transaction, revealed in a recent filing with the Securities and Exchange Commission, occurred during the final quarter of the past year. It appears Readystate, having once held a substantial stake, has reduced its position to a mere whisper – a paltry 10,000 shares remaining from an original cast of over 371,000. A veritable rout, wouldn’t you agree? One pictures the fund manager, perhaps, clutching his ledgers and lamenting the follies of the market.

Eli Lilly currently reigns supreme in this peculiar kingdom, with Novo Nordisk as its somewhat less dazzling courtier. But the gates are not closed. Viking Therapeutics, a name that conjures images of both adventure and, shall we say, robust constitutions, is poised to enter. Their trials, thus far, suggest a competence that is, if not startling, certainly…sufficient.

For months, Nebius had been the object of considerable attention, a rising star fueled by contracts with those ambitious artificial intelligence companies. A gain of 350% in a year is, of course, remarkable. One wonders, though, if such rapid ascent is ever truly sustainable, or merely a fleeting illusion.

BYD, or Build Your Dreams, which feels less like a corporate slogan and more like a passive-aggressive suggestion from a life coach, is releasing its earnings report soon. The stock’s been down, which, honestly, is the most interesting thing about it. It’s down 17% in the last year. That’s… a correction, right? Or is it just the universe gently suggesting I avoid making any impulsive decisions?